Cystic fibrosis

The PBS subsidises ivacaftor for patients aged 2 years or older with cystic fibrosis.

Patient eligibility

Treatment with ivacaftor can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 100 for a patient with cystic fibrosis.

Patients must be eligible for the PBS and meet the relevant restrictions criteria.

The Schedule of Pharmaceutical Benefits outlines restrictions for prescribing ivacaftor.

Section 100 arrangements

This item is only available for day admitted patients, non-admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public participating hospital, or
  • a public hospital

This item is not PBS subsidised for hospital in-patients. You must include the hospital name and provider number on the authority application form.

Applications

Patients must be:

  • assessed through a cystic fibrosis clinic or centre which is under the control of specialist respiratory physicians with expertise in the management of cystic fibrosis. If a patient is in a remote location, a consulting physician from a cystic fibrosis clinic can manage and prescribe the patient
  • registered with Australian Cystic Fibrosis Database Registry

Initial treatment

Make all initial applications for authority approval to prescribe ivacaftor for the treatment of cystic fibrosis in writing and:

All applications must include the completed:

Continuing treatment

Make all applications for continuing authority approval to prescribe PBS subsidised ivacaftor for the treatment of cystic fibrosis in writing and:

All applications must include a completed:

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 June 2018